<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865525</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14.084</org_study_id>
    <nct_id>NCT02865525</nct_id>
  </id_info>
  <brief_title>Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring.</brief_title>
  <acronym>QUILAM</acronym>
  <official_title>QUILAM : Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medication non-adherence is an economic problem and a major public health challenge. Factors&#xD;
      influencing medication adherence can be modelled according to five dimensions: disease,&#xD;
      medication, patient and its close relatives, demographic and socioeconomic factors and health&#xD;
      care system. A tool is needed to qualify medication adherence in order to adapt tailored&#xD;
      support for individual patients to promote and optimize adherence to therapy.&#xD;
&#xD;
      The objective of this work is to present the preliminary results of QUILAM project which is&#xD;
      divided into 3 phases: 1. Development of a tool to assess barriers to medication adherence in&#xD;
      chronic patient (COPD, Heart failure, Type 2 diabetes) ; 2. Validation of the instrument&#xD;
      (especially against clinical criteria) ; 3. Evaluation of the sensitivity of the tool during&#xD;
      educational interventions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Number of events 'hospitalization and death' for 2 patient groups defined through the questionnaire QUILAM score</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility and acceptability of the questionnaire (duration / missing data)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability over time of the questionnaire (test-retest J0 - J15)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>External construct validity (Girerd, SatMedQ, BMQ)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical events for 2 patient groups</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of events 'hospitalization and death' for 2 patient groups separate with different cut off</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">282</enrollment>
  <condition>Patient Education as Topic</condition>
  <condition>Surveys and Questionnaires</condition>
  <condition>Medication Adherence</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        targeted pathologies: type 2 diabetes heart failure Chronic obstructive pulmonary disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with at least one of the following pathologies: diabetes type II, COPD, heart&#xD;
             failure&#xD;
&#xD;
          -  person available for a follow-up of 1 year&#xD;
&#xD;
          -  Affiliated to the social security or recipient of such a regime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons referred to in articles L1121-5 and L1121-8 in the french public health code&#xD;
&#xD;
          -  Patient who do not speak french&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beno√Æt ALLENET, PharmD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>TIMC-IMAG UMR 5525 / ThEMAS, University Grenoble-Alpes/ Grenoble University Hospital, Grenoble, France/</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurelie Gauchet, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Inter-University Laboratory of Psychology (LIP), University Grenoble-Alpes, Grenoble, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surveys and Questionnaires</keyword>
  <keyword>Patient Education as Topic</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

